Clinical Grade Non-Transfusable Mobilized Peripheral Blood CD1c (BDCA-1)+ Cells, G-CSF + Plerixafor, Frozen
CD1c (BDCA-1) is expressed on myeloid dendritic cells (MDCs), also referred to as conventional dendritic cells, that also highly express MHC class II. Upon infection, MDCs become activated and promote adaptive immune responses. Additionally, CD1c is expressed on some B cells.
Human mobilized peripheral blood CD1c+ cells are enriched from the total cell population using indirect immunomagnetic anti-CD1c beads. All cell isolation components, including reagents, tubing sets, instruments, and buffers, are manufactured and controlled under an ISO 13485 certified quality system under FDA oversight. Cell culture procedures, including open manipulation of vials, final filling, and closure of finished products, are performed inside ISO 5 air quality processing chambers located within an FDA-registered cell manufacturing facility. Isolated primary cells are characterized by flow cytometry to ensure a highly pure and viable cell population.
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols. All reagents and devices used to collect and separate the cells are certified clinical grade. This item is for research use only.
|Cell and Tissue Source||Peripheral Blood|
|Product Type||Primary Cells|
|Cell Type||Dendritic Cells|
|Donor Attributes||HIV-, HepB-, HepC-|
|Purity||≥85% by Flow Cytometry|
|Viability||≥70% by Flow Cytometry|
|Contains||CryoStor™ CS10 (10% DMSO)|
|Injections||10μg/kg/day of G-CSF & 240μg/kg Plerixafor the day before collection|